Objective: To analyze whether two dietary weight loss interventionsFthe dietary approaches to stop hypertension (DASH) program and a low-fat diet programF would be cost-effective in Australia, and to assess their potential to reduce the disease burden related to excess body weight. Design: We constructed a multi-state life-table-based Markov model in which the distribution of body weight influences the incidence of stroke, ischemic heart disease, hypertensive heart disease, diabetes mellitus, osteoarthritis, post-menopausal breast cancer, colon cancer, endometrial cancer and kidney cancer. The target population was the overweight and obese adult population in Australia in 2003. We used a lifetime horizon for health effects and costs, and a health sector perspective for costs. We populated the model with data identified from Medline and Cochrane searches, Australian Bureau of Statistics published catalogues, Australian Institute of Health and Welfare, and Department of Health and Ageing. Outcome measures: Disability adjusted life years (DALYs) averted, incremental cost-effectiveness ratios (ICERs) and proportions of disease burden avoided. ICERs under AUS$50 000 per DALY are considered cost-effective. Results: The DASH and low-fat diet programs have ICERs of AUS$12 000 per DALY (95% uncertainty range: Cost-savingF68 000) and AUS$13 000 per DALY (Cost-savingF130 000), respectively. Neither intervention reduced the body weight-related disease burden at population level by more than 0.1%. The sensitivity analysis showed that when participants' costs for time and travel are included, the ICERs increase to AUS$75 000 per DALY for DASH and AUS$49 000 per DALY for the low-fat diet. Modest weight loss during the interventions, post-intervention weight regain and low participation limit the health benefits. Conclusion: Diet and exercise interventions to reduce obesity are potentially cost-effective but have a negligible impact on the total body weight-related disease burden.
Introduction
Overweight and obesity in adults is a global public health concern because excess weight increases the relative risk of disease and mortality. [1] [2] [3] A range of highly prevalent diseases, notably cardiovascular disease, diabetes and a number of cancers, have been proven to be directly related to excess weight. 4 In 1999-2000, 67% of Australian men and 52% of women were classified as overweight or obese. 5 High body mass was responsible for 7.5% of the total burden of disease and injury in Australia in 2003. 6 Overweight and obesity have been estimated to cost the Australian society AUS$10.2 billion (BUSD 7.7 billion) in 2005. 7 Many interventions are designed to reduce excess weight in adults. The most common involve a reduced calorie diet, exercise or a combination of both. Other common interventions are pharmaceuticals, surgery and population-wide measures such as advertising campaigns encouraging healthy eating and physical activity.
Effective weight loss depends on decreased energy intake, increased dietary quality and increased physical activity. 3 Interventions to reduce weight in overweight and obese subjects range in effectiveness. An obese person may lose 5-8.5 kg with diet, 8 1-2 kg with exercise, 9 2.5-5.5 kg with drugs 10 or 20-30 kg with surgical treatment.
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Cost-effectiveness is one of the criteria considered when deciding whether to fund preventive health interventions. This study forms part of the Assessing Cost-Effectiveness in Prevention (ACE Prevention) project, which was established to provide a comprehensive analysis of the cost-effectiveness of interventions that address the noncommunicable disease burden. The project takes a health sector perspective, that is, costs to individuals and government are considered. The rationale and methodology have been explained elsewhere. 12 Previous studies that were part of ACE prevention reported on physical activity and alcohol interventions. 13, 14 We recently reported that 'traffic-light' nutrition labelling and 'junk-food' tax offer excellent value for money as obesity prevention measures. 15 Using the same methods, the present research evaluates whether two dietary interventions to reduce overweight and obesity would be cost-effective in the Australian context.
Materials and methods

Interventions
We reviewed the weight loss literature and found a range of diet interventions which would be suitable for implementation in Australia, and had evidence of efficacy. A recent meta-analysis of diet and exercise programs synthesized the results of 46 trials of dietary counseling, revealing a treatment effect of À1.9 body mass index (BMI) units at 12 months. 16 The authors also found that the interventions, study samples and weight changes were heterogeneous. In order to accurately cost a potential program and model the resulting weight loss, it was thus necessary to select specific trials. As the costing depends on the intensity of interventions, we decided to select one intervention in the middle range of intensity and effectiveness, the dietary approaches to stop hypertension (DASH) diet and exercise program. This program achieved a mean body mass reduction of 5.8 kg, which translates to 1.9 BMI units for a 1.75 m person. We also assessed a less resource intensive intervention that was trialed in New Zealand, where it showed an average weight reduction that was slightly smaller at 3.9 kg, or about 1.3 BMI units. Data sources and assumptions are listed in Supplementary Appendix 1.
The DASH diet is a well-established diet and exercise program from the United States, which has proven to reduce weight by 5.8 kg on average. [17] [18] [19] It emphasizes consumption of fruit, vegetables, low fat dairy products, whole grains, poultry, fish and nuts and the reduced consumption of fats, red meat, sweets and sugar-containing beverages. The trials that evaluated the DASH diet 17, 19, 20 also recommended 180 minutes per week of moderate intensity physical activity in conjunction with the diet. Participants in the trials were recruited using mass mailings, community-based screening and mass-media announcements. The trials provided ten group-based and two individual meetings with dieticians. In addition, there were two group meetings and two individual meetings with exercise physiologists over a 6-month period. Participants also kept food diaries, recorded physical activity and monitored intake of calories, sodium, fruit, vegetables, dairy products and fat.
The diet-only intervention ('low-fat diet') is based on a randomized controlled trial conducted in New Zealand among working persons aged 40 years and above, in whom glucose intolerance had been found 2 years earlier. 21 This diet emphasizes reducing fat intake, while maintaining adequate levels of micro-and macro-nutrients. Participants in the 1-year program participated in education about reducing dietary fat intake, personal goal setting, selfmonitoring and evaluation through a series of monthly small group meetings with dieticians. In addition, subjects completed shorthand food diaries, which were reviewed at the monthly meetings. In our analyses, the target group of the dietary interventions consisted of all overweight and obese Australians aged 20 and above in 2003 (65% of men and 55% of women). 5 Recruitment was assumed to be through mass-media campaigns and postal mailings, and a self-selected 4.3% of the target population was expected to participate. This participation rate was based on response rates observed in other preventive health trials (Supplementary Appendix 1).
Intervention effectiveness
Published results are available for two trials of the DASH intervention: the PREMIER and weight-loss maintenance (WLM) clinical trials. 17, 20 After 6 months on the DASH program, average weight loss in the intervention group was 5.8 kg in both trials, with standard deviations of 5.8 in the PREMIER trial and 4.4 in the larger WLM trial. Because of its greater sample size of 1685 participants, we based our effect estimates on the WLM trial. 20 Neither trial had a suitable control group. The 'advice only' group in the PREMIER trial received a 30 min behavioral intervention immediately after randomization. This intervention was led by a dietician who discussed weight, sodium intake, physical activity and the basic DASH diet. We did not consider this an appropriate control condition for our evaluation. The WLM trial did not have a control group. We therefore based the analysis on the weight change in the group that received the DASH intervention compared with a synthetic control group that experienced only the weight change resulting from the secular trend in BMI, which over the 6 months of the trial would have added an average of 0.13 kg, depending on age and sex. A trial of the low-fat diet found that total fat and saturated fat intake had decreased significantly at the end of the 12-month trial period, whereas consumption of micronutrients was not compromised. The amount of weight lost compared with the control group was 3.9 kg at 1 year (standard error 1.25). 21 Modeling health outcomes and costs The model is described in Supplementary Appendix 2. Briefly, we constructed a multi-state life Effectiveness. Effectiveness is modeled by dividing each population into 5-year cohorts and simulating each cohort until all persons have died or reached 100 years of age. The model explicitly simulates nine obesity-related diseases: stroke, ischemic heart disease, hypertensive heart disease, diabetes mellitus, osteoarthritis, post-menopausal breast cancer, colon cancer, endometrial cancer and kidney cancer. 4 Estimates of disease incidence, prevalence and mortality are based on the Australian Burden of Disease 2003 study. 6 For each disease, a simple disease model calculates the effect on prevalence and disease-specific mortality as a consequence of changes in disease incidence. 23 Years of life lived are adjusted at each age for time spent in poor health because of disease or injury. Each disease state was assigned a disability weight based on the Australian Burden of Disease Study. 6 The model summarizes the disease-specific changes in the number of years lived adjusted for disability from the explicitly modeled diseases and average age-and sexspecific disability levels from all other causes. The reference population is simulated on the basis of the measured current body-weight distribution 5 and expected future trends in overweight and obesity in Australia. 24 The characteristics of the intervention population are the same except that the overweight and obese lose a number of kilograms, which lowers the risk of each of the diseases related to excess weight. The change in disease morbidity and mortality is calculated through Potential Impact Fraction calculations. 25 The particular procedure used was the 'relative risk shift' method, in which prevalence remains stable but the risk of disease varies because of the intervention. The procedure and the relative risks used 4, 26 are detailed in Supplementary Appendix 2.
The effect of weight regain. Weight that is lost with diet and exercise programs tends to be regained. 27, 28 A recent metaregression found that, on average, participants in diet and exercise programs keep the weight off for 6 months but then commence regaining weight at a rate of 0.03. BMI-point per month until, at around 5.5 years post-intervention, no effect is left. 16 We based our modeling on this evidence and assumed that weight gain commenced at this rate at the end of the active phase of the interventions (that is, at 6 months for the DASH diet and at 12 months for the low-fat diet), and that no residual weight loss remains indefinitely.
Costs. Intervention costs were estimated on the basis of the reported use of resources, supplemented with information from the authors of the trials. Start-up costs were excluded (for example, infrastructure costs) with all interventions assumed to be operating under steady-state conditions. Supplementary Appendix 1 summarizes the assumptions and costing figures. The intervention costs were partially offset by reduced health care expenditure for diseases related to overweight and obesity in later years. For cancers, these costs were evaluated for each incident case averted and for the remaining diseases for each prevalent case averted. Disease treatment costs were drawn from the Australian Institute of Health and Welfare 29 and are detailed in Supplementary Appendix 2.
All costs were adjusted to real prices in the 2003 reference year using the relevant Health Price Index from the Australian Institute of Health and Welfare, 29 or the Consumer Price Index from the Australian Bureau of Statistics 30 if the costs occurred outside the health sector. We present three costing scenarios for each intervention. In the base case scenario, we used a health sector perspective and included only intervention costs that accrue to governments/ health insurers and the lifetime costs of health care for obesityrelated diseases. The second scenario additionally includes participants' travel costs and the cost of time spent participating in the intervention. Participants' time was valued at 25% of the wage rate, 31 which was determined by considering the proportions of the populations who are employed, unemployed or 'not in the work-force'. 32 This came to AUS$17.44
per hour, which we used for all time costs regardless of age and sex. The third scenario includes time and travel costs, and the costs for health care because of unrelated diseases in the years of life that were added by interventions.
33 Table 1 gives a summary of the intervention effects and costs of the interventions.
Calculation of disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (ICERs). We calculated DALYs averted by the intervention, as the increase in the discounted number of DALYs lived in the intervention population compared with the population that is exposed to the trend in BMI only. To show the impact of interventions on the total burden of high body mass in the Australian population, we also expressed the health gains at the population level as a percentage of the gains that could be achieved under an ideal scenario in which the population has a BMI distribution with a mean of 21 and a s.d. 1, the theoretical minimum scenario used in the World Health Organization's Comparative Risk Assessment study. 34 We Sensitivity analyses. In addition to the costing scenarios mentioned above, we explored the range of cost-effectiveness outcomes by setting the discount rate to 0% (scenario 4) and by halving the rate at which weight is regained (scenario 5).
For the diet-only intervention, we also explore a scenario in which the weight regain is based on trial data 21 rather than on meta-regression (scenario 6). 16 Finally, because adherence in realistic circumstances is likely to be less than in trials, we doubled the non-attendance at the sessions of each intervention, from 14 to 28% for DASH and from 23 to 46% for the low-fat diet. We assumed this would lead to a proportional reduction in effects on BMI while leaving costs unchanged (scenario 7).
Validation. To examine the validity of the model, we predicted mortality rates over 10 years from any cause at different levels of BMI, assuming BMI stable over the lifetime. We compared the results with those of large cohort studies.
Other policy-relevant considerations
To further assist policy makers, we undertook a 'second stage filter' analysis and examined the interventions on the strength of evidence, impact on inequalities, acceptability to stakeholders, feasibility, sustainability and relevance to the indigenous population. As policy is often based on targets in terms of proportions of the population being overweight or obese, and the model does not produce this as an outcome (for technical reasons it changes risk of disease, not body mass), we performed a separate calculation to estimate the maximum effect on the prevalence of overweight (including obesity), assuming a scenario in which the entire population starts the intervention at the same time. This results in a shift in mean BMI, which we used to recalculate the distribution of BMI at every age-sex category. We then determined the age-weighted prevalence of BMI425, and multiplied this by the participation rate.
Results
The total loss of DALYs due to excess body mass over the lifetime of Australians aged 20 years and above in 2003, was 5.8 million (95% confidence range 4.9-6.6 million). Neither of the evaluated interventions averts more than 0.1% of this disease burden (Table 2) . An intervention is deemed to be 'cost-saving' (sometimes called 'dominant') if it results in both a health gain and net cost savings (taking into account intervention costs and future health care costs saved as a result of cases of disease prevented). It is customary not to report negative ICERs as these are uninterpretable. Both the DASH diet and exercise intervention, and the low-fat diet have central ICER estimates well below the AUS$50 000 per DALY threshold when the cost of participants' time and travel are ignored (Table 2) . If these costs are included, the ICERs are AUS$75 000 per DALY and AUS$49 000 per DALY, respectively, and the interventions have a 39 and 43% probability of being considered cost-effective. Subsequent addition of the cost of health care for unrelated diseases in the additional life years moves the ICERs slightly further in an unfavorable direction.
When costs and effects are not discounted, the costs per DALY are more than halved. The results are also very sensitive to the rate of post-intervention weight regain and to attendance rates (Table 3) .
Compared with optimum BMI levels, the 10-year all-cause mortality rates among the overweight and obese predicted by our model rise with age up to about 52 years of age for men (RR ¼ 1.41) and 67 years for women (RR ¼ 1.40) and attenuate in old age ( Table 4) .
The main considerations in the second stage filter analysis were that the uptake of both drugs and diets is likely to be greater among persons with higher socioeconomic status, thus potentially increasing inequalities. On the other hand, risk factor exposure, and thus eligibility for the interventions, is higher in lower SES groups. Shortages of dieticians and exercise physiologists may limit the capacity for diet and exercise interventions, especially in rural areas. Because of these capacity shortages, SES-related lower uptake and cultural barriers, indigenous Australians might benefit less than average from these interventions unless targeted efforts are undertaken.
Discussion
When participants' time and travel are ignored, the diet and exercise, and the low-fat diet interventions could be considered cost-effective. However, the interventions can prevent only a small fraction of the disease burden related to excess body mass, and the effects on the prevalence of overweight and obesity would be too small for surveys to detect.
If weight regain could be avoided, even interventions that result in modest weight loss would be cost-effective for the 4700 (Cost-savingF15 000) 6200 (Cost-savingF70 000) Rate of weight regain halved (scenario 5) 620 (Cost-savingF26 000) 3000 (Cost-savingF96 000) Weight regain as observed in trial 21 rather than from meta-regression 16 (scenario 6) F 6600 (Cost-savingF30 000) Non-attendance doubled (scenario 7)
20 000 (4 400-49 000) 32 000 (5900-210 000
Abbreviation: DASH, dietary approaches to stop hypertension. Values are 'ratios of means' 50 (mean incremental costs over mean DALY changes) and 95% uncertainty intervals in Australian dollars referenced to the year 2003 per DALY. An intervention is deemed to be 'cost-saving' if it results in both a health gain and net cost savings (taking into account intervention costs and future health care costs saved as a result of cases if disease prevented). It is customary not to report negative ICERs, as these are uninterpretable. Cost-effectiveness of weight-reducing diets M Forster et al
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Australian health care system. The current evidence base is limited to short-term interventions, which result in weight loss that is reversed rather quickly after the active intervention has ended. The WLM Trial 20 is currently analyzing alternative strategies to maintain weight loss during a 30-month period after a DASH intervention. The results after the initial 6-month trial have found that keeping a food diary can increase weight loss, but longer term results are still needed. Regular meetings with dieticians and exercise physiologists increase the effectiveness of diet and exercise interventions and may also be important for weight maintenance. 16 Achieving prolonged WLM is likely to require ongoing activity, and would also incur costs beyond that of a one-off 6-or 12-month intervention.
Whether an intervention is considered cost-effective depends on what costs are included. Adding the costs of participants' time and other expenses to attend the sessions greatly increases the cost-effectiveness ratios. It would be perilous to ignore time costs; they represent real costs to the participants, most of whom are time poor. On the other hand, for persons who positively value the sessions, the ratios that ignore time and travel costs are a better guide to decide whether an intervention is worthwhile. The same is true for health care funders who are mainly interested in their own share of the costs. Health care funders may also wish to consider the health care costs in the added years of life.
Comparison of results with other studies
Our estimates for the cost-effectiveness of the dietary interventions compare favorably with those we recently estimated for weight watchers. 37 Comparison with other studies is difficult because of differences in assumptions and model structures, but most published studies found costeffectiveness ratios for diet and exercise interventions similar to ours [38] [39] [40] unless weight regain was assumed zero. 41 Our study modeled the Australian adult population, but given comparable disease patterns, health care expenditure, prices and culture, the results can be considered indicative for other western countries as well.
Limitations
Several limitations should be mentioned. The benefits of exercise and diet are only modeled through reductions in BMI, whereas improved diet and increased physical activity can be expected to have health benefits independent of BMI. Furthermore, this study concentrated on expected disease outcomes and did not attribute any value to weight loss per se, general welfare or happiness. It has been argued that weight loss is accompanied by improved mental health, fitness and wellbeing even in the absence of changes in disease status. Adding such effects could considerably improve the cost-effectiveness estimates. 42 We only modeled two diet and exercise interventions, out of a plethora of similar programs. Our results therefore cannot be generalized to all interventions with diet and exercise components.
Both interventions had a relatively high participation rate and a low drop-out rate. Also, the low-fat diet was conducted among persons in whom glucose intolerance was established. Their knowing to be at higher risk may have increased participants' adherence. This improves the estimated cost-effectiveness because it decreases the likelihood that a participant will incur costs but not lose weight.
Our modeling accounts for expected future trends in overweight and obesity, but no future trends in disease incidence and mortality were modeled. If the incidence and mortality caused by overweight and obesity-related disease decreases, for example because of improved prevention and care, this would slightly deteriorate the cost-effectiveness of the interventions in future years.
The risk of mortality of any cause that our model predicts rises less steeply with BMI than it does in cohort studies, especially for women. [43] [44] [45] Several factors are likely to contribute to this difference. First, some of the studies we compared with were done in the US at the peak of the cardiovascular disease 'epidemic'. The large decrease in obesity-related disease rates is likely to have reduced the obesity-related mortality risks. 46 Second, our model only assumes an effect of BMI on disease incidence and ignores any influence obesity may have on mortality risks, given the presence of a disease. However, the debate around the 'obesity paradox' shows considerable uncertainty regarding the effects of overweight and obesity on disease survival. 47 Lastly, obesity may increase mortality for diseases that we did not include in our model. Our model may thus underestimate the health effects of BMI reductions and bias cost-effectiveness results in a direction unfavorable to the interventions we modeled. Consistent with our health sector perspective, our study does not take into account any increases in productivity that may result from reduced BMI. Including these benefits would improve the cost-effectiveness of all four interventions. In a societal perspective, however, this would wholly or partially be offset by an increased number of older people, who tend to consume more than they produce.
In conclusion, our research assesses the probable costeffectiveness of the DASH diet and exercise intervention, and a low-fat dietary intervention in the Australian health care system. When only health care costs are considered, the dietary interventions can be considered a reasonably good investment. When participants' time investments are also considered this becomes doubtful. Future research could focus on influencing those who have lost weight to maintain this result. Based on current evidence, the overall effect of these interventions on the obesity-related burden of disease is negligible. Evidence from tobacco control, 48 alcohol 14 and physical activity 13 suggest that population-targeted inter-
ventions (for example, taxes and restrictions of advertising
Cost-effectiveness of weight-reducing diets M Forster et al and sales) have the greatest impact on population health. Similar approaches may be required to turn the 'obesity epidemic' around. Research should therefore also be conducted on interventions that change the 'obesogenic' environment and target whole populations rather than individuals. 49 
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